

transgenic animal, collecting the milk, and isolating the polypeptide therefrom.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 60 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: April 17, 1998.

Jack Spiegel,

Director, Division of Technology Development and Transfer, Office of Technology Transfer.

[FR Doc. 98-11113 Filed 4-24-98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License: Use of Short WAP Promoter in Mammary Tissue of Transgenic Animals

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive license worldwide to practice the invention embodied in: U.S. Patent Application Serial No. 08/246,259, filed May 19, 1994, entitled "Transgenic Animals Secreting Desired Proteins Into Milk" to Genzyme Transgenics Corporation, having a place of business in Framingham, Massachusetts. The patent rights in these inventions have been assigned to the United States of America.

The field of use will be the use of the invention for the production in transgenic animals of alpha interferon, alpha-1 proteinase inhibitor, angiogenin, antithrombin III, beta interferon, calf intestine alkaline phosphatase, cystic fibrosis

transmembrane regulator, Factor X, glutamic acid decarboxylase, human growth hormone, human serum albumin, insulin, longer acting tissue plasminogen activator, myelin basic protein, pro-insulin, prolactin, tissue plasminogen activator, soluble CD4 HIV receptor, the recombinant monoclonal antibody against Lewis Y antigen designated BR96, and the monoclonal antibody designated CTLA4 Ig.

DATES: Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before June 26, 1998 will be considered.

ADDRESSES: Requests for a copy of the patent applications, inquiries, comments and other materials relating to the contemplated license should be directed to: Leopold J. Luberecki, Jr., J.D., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Box 13, Rockville, MD 20852-3804; Telephone (301) 496-7735, ext. 223; Facsimile: (301) 402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent application.

SUPPLEMENTARY INFORMATION: The patent application claims a transgenic, non-human mammal containing a gene that encodes a protein, the gene being under the transcriptional control of a mammalian milk protein promoter which does not naturally control the transcription of the gene, the DNA sequence further including DNA enabling secretion of the protein. The promoter can be that of a milk serum protein, which includes the whey acid protein (WAP) or a casein protein. The invention permits the production of a desired protein in a living domesticated mammal, which is capable not only of producing the desired protein, but preferably of passing on the ability to do so to its female offspring. The present invention specifically includes an exogenous DNA sequence that has the 5' 2.6 kb promoter fragment of hte mouse whey acid protein (WAP) gene.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 60 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments

and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: April 17, 1998.

Jack Spiegel,

Director, Division of Technology Development and Transfer, Office of Technology Transfer.

[FR Doc. 98-11114 Filed 4-24-98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License: Spectroscopic Imaging Device Employing Imaging Quality Spectral Filters

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice in accordance with 15 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive license to practice the invention embodied in U.S. Patent Number 5,377,003 and U.S. Patent Application Number 08/996,497, entitled "Spectroscopic Imaging Device Employing Imaging Quality Spectral Filters", to Spectral Dimensions, Inc., having a place of business in Boston, Massachusetts. The patent rights in this application have been assigned to the United States of America.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7 and may be limited to the field of use of veterinary and human clinical diagnosis.

DATES: Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before June 26, 1998 will be considered.

ADDRESSES: Requests for a copy of this patent application, inquiries, comments, and other materials relating to the contemplating license should be directed to: John Fahner-Vihetic, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; Telephone: 301/496-7735 ext. 270; Fax: 301/402-0220; e-mail: jf36z@nih.gov. A signed Confidentiality Agreement will be required to review copies of the patent application.

SUPPLEMENTARY INFORMATION: The present technology is a novel imaging device and methodology which integrates both light microscopy and spectroscopy. This invention allows for the cost-effective development of high-resolution spatial, chemical, and spectral images. It provides a rapid means for examining and collecting large format images from vibrational and visible spectra in a three-dimensional sample. It is superior to current equipment because it has no moving parts. This device may be used as a tool for the characterization of polymers, semiconductors, contamination studies, analysis of diffusion and failure mechanisms, and has potential as a diagnostic tool of clinical analysis of histologic materials.

The prospective exclusive license may be granted unless, within 60 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7. Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license.

Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: April 17, 1998.

Jack Spiegel,

Director, Division of Technology Development and Transfer, Office of Technology Transfer.

[FR Doc. 98-11111 Filed 4-24-98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[CA-930-5410-00-B097; CACA 38636]

Conveyance of Mineral Interests in California

AGENCY: Bureau of Land Management, Interior.

ACTION: Notice of segregation.

SUMMARY: The private land described in this notice, aggregating 5.00 acres, is segregated and made unavailable for filings under the general mining laws and the mineral leasing laws to determine its suitability for conveyance of the reserved mineral interest pursuant to section 209 of the Federal Land Policy and Management Act of October 21, 1976. The mineral interests

will be conveyed in whole or in part upon favorable mineral examination. The purpose is to allow consolidation of surface and subsurface of minerals ownership where there are no known mineral values or in those instances where the reservation interferes with or precludes appropriate nonmineral development and such development is a more beneficial use of the land than the mineral development.

FOR FURTHER INFORMATION CONTACT:

Kathy Gary, Bureau of Land Management, California State Office, 2135 Butano Drive, Sacramento, California 95825, (916) 978-4677.

Mount Diablo Meridian

T. 33 N., R. 9 W.,

Sec. 17, E $\frac{1}{2}$ SE $\frac{1}{4}$ NW $\frac{1}{4}$ NW $\frac{1}{4}$.

County—Trinity

As Reservation—All coal and other minerals.

Upon publication of this Notice of Segregation in the **Federal Register** as provided in 43 CFR 2720.1-1(b), the mineral interests owned by the United States in the private lands covered by the application shall be segregated to the extent that they will not be subject to appropriation under the mining and mineral leasing laws. The segregative effect of the application shall terminate by publication of an opening order in the **Federal Register** specifying the date and time of opening; upon issuance of a patent or other document of conveyance to such mineral interest; or two years from the date of publication of this notice, whichever occurs first.

Dated: April 17, 1998.

David McNay,

Chief, Branch of Lands.

[FR Doc. 98-11063 Filed 4-24-98; 8:45 am]

BILLING CODE 4310-40-P

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[WY-985-0777-66; WY-142430]

Proposed Lease of Public Lands Under the Recreation and Public Purposes Act in Washakie County, Wyoming, Bighorn Basin Resource Area

ACTION: Notice of realty action.

SUMMARY: The following public lands near the community of Worland, Washakie County, Wyoming, have been examined and found suitable for classification for lease under the provisions of the Recreation and Public Purposes Act, as amended (43 United States Code 849 *et seq.*) The Washakie County Fair Board proposes to use the lands for an Olympic-style cross-

country horse track and associated jumping facilities.

Sixth Principal Meridian

T. 48 N., R. 93 W.,

Sec. 8, S $\frac{1}{2}$ SE $\frac{1}{4}$ SE $\frac{1}{4}$ NE $\frac{1}{4}$, NE $\frac{1}{4}$ SE $\frac{1}{4}$.

Sec. 9, E $\frac{1}{2}$ W $\frac{1}{2}$ SW $\frac{1}{4}$ NW $\frac{1}{4}$,

E $\frac{1}{2}$ SW $\frac{1}{4}$ NW $\frac{1}{4}$, NW $\frac{1}{4}$ SW $\frac{1}{4}$,

NW $\frac{1}{4}$ SW $\frac{1}{4}$ SW $\frac{1}{4}$ NW $\frac{1}{4}$,

W $\frac{1}{2}$ NW $\frac{1}{4}$ NW $\frac{1}{4}$ SE $\frac{1}{4}$,

E $\frac{1}{2}$ NE $\frac{1}{4}$ NE $\frac{1}{4}$ SW $\frac{1}{4}$.

Containing 127.5 acres more or less.

FOR FURTHER INFORMATION CONTACT:

Bureau of Land Management, Worland District Office, Steven R. Till, Realty Specialist, P.O. Box 119, Worland Wyoming 82401-0119, or telephone (307) 347-5100.

SUPPLEMENTARY INFORMATION: The lands are not needed for federal purposes. Lease of the lands would be consistent with current BLM land use planning and would be in the public interest.

The lease would be subject to the following terms and conditions:

1. Provisions of the Recreation and Public Purposes Act and to all applicable regulations of the Secretary of the Interior.

2. All valid existing rights (for example, rights-of-way, permits and leases). Detailed information concerning this action is available for review at the office of the Bureau of Land Management, Worland District, 101 S. 23rd Street, Worland, Wyoming.

Upon publication of this notice in the **Federal Register**, the lands will be segregated from all other forms of appropriation under the public land laws, including the general mining laws, except for lease under the Recreation and Public Purposes Act and leasing under the mineral leasing laws. For a period of 45 days from the date of publication of this notice in the **Federal Register**, interested persons may submit comments regarding the proposed classification of the lands to the District Manager, Worland District Office, P.O. Box 119, Worland WY 82401-0119.

Classification Comments: Interested parties may submit comments involving the suitability of the land for a cross-country horse track and associated jumping facilities. Comments on the classification are restricted to whether the land is physically suited for the proposal, whether the use will maximize the future use or uses of the land, whether the use is consistent with local planning and zoning, or if the use is consistent with state and federal programs.

Application Comments: Interested parties may submit comments regarding the specific use proposed in the application and plan of development, whether the BLM followed proper